treatment of the spinal cord injured animal. Those include treatment by Metatyrozine by Osterholm and his associates, also Metatyrozine by Yeo and his associates from Australia, and Rezerpine by myself and my colleagues. Unfortunately these drugs are not suitable for treatment of human spinal cord injuries. In the present experimental work we have used Marcaine, a long-acting local anaesthesia which abolish or diminish the secondary effect. I don't know about Dopamine, there have been a lot of papers about Dopamine. Whatever those mechanisms are I want to prevent or to reduce that secondary effect, I think that this drug we have used is promising and I hope that I would follow up the research.
PROFESSOR ROSSIER. I think that we are very much interested in this but the question was how was the Marcaine introduced? The technicality of the introduction of the Marcaine, am I correct? DR SUSSMANN. Yes. DR REZAIAN. Marcaine is one of these local anaesthetic drugs, their chemical name is biotetrocyne and is produced by one of the Swedish manufacturers with Foley catheter, in any ward you have two ways, one is that one tube is going to the sac which will produce pressure for 15 minutes, pressure of 400 for 15 minutes if you do it first.
PROFESSOR ROSSIER. I'm sorry this is not exactly the question. DR REZAIAN. We put through the tube a drip.
PROFESSOR SUSSMAN. No, we understand that, but we are calling to your attention simply that the chemical agents are inaugurated in the central grey of the spinal cord and it is hard to understand how an agent introduced in the extra-dural space, you can get a sympathetic blockade that way and that you can reduce blood pressure and get a bradycardia. It is hard to understand how that will effect the chemical events be it intrathecally or intramedulary. So could you tell us? DR REZAIAN. I have no more details. PROFESSOR ROSSlER. Thank you very much.
